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A B S T R A C T   
Autism spectrum disorder (ASD) and obsessive compulsive disorder (OCD) show overlapping symptomatology 
and deficits in inhibitory control, which are associated with altered functioning and glutamatergic signaling in 
fronto-striatal circuitry. These parameters have never been examined together. The purpose of the current study 
was to investigate functioning during inhibitory control and its association with fronto-striatal glutamate con-
centrations across these disorders using a multi-center, longitudinal approach. Adolescents with ASD (n = 24), 
OCD (n = 15) and controls (n = 35) underwent two magnetic resonance imaging (MRI) sessions with a one-year 
interval. This included proton magnetic resonance spectroscopy (1H-MRS; n = 74) and functional MRI during an 
inhibitory control task (n = 53). We investigated 1H-MRS data and fMRI data separately as well as integrated in a 
multimodal analysis using linear models focusing on diagnosis and continuous measures of overlapping 
compulsivity symptoms. ACC glutamate was reduced over time in the ASD group compared with controls, while 
striatal glutamate decreased over time independent of diagnosis. Increased compulsive behavior seemed to be 
associated with increased striatal activity during failed inhibitory control. The integrated analyses showed dif-
ferential involvement of increased striatal glutamate during failed but decreased striatal glutamate during suc-
cessful inhibitory control in the OCD group compared to controls and ASD, suggesting different underlying 
mechanisms for OCD compared to ASD.   
1. Introduction 
Although autism spectrum disorder (ASD) and obsessive compulsive 
disorder (OCD) are two separate neurodevelopmental disorders with 
distinct diagnostic characteristics (American Psychiatric Association, 
2013), they are highly comorbid and a comparison of symptoms has 
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suggested more similarities than differences between the two (Robbins 
et al., 2012; Anholt et al., 2010; Zandt et al., 2007). However, not much 
is known about underlying mechanisms of the behaviors common 
among those with these disorders; restricted and repetitive patterns of 
behavior and/or compulsivity. The latter is defined as a repetitive, 
irresistible urge to perform certain behaviors or thoughts, and dimin-
ished control over this urge (Chamberlain and Menzies, 2009). Repeti-
tive and compulsive behaviors are associated with deficits in inhibitory 
control in tasks such as the stop-signal task (Anholt et al., 2010; 
Chamberlain et al., 2007). Fronto-striatal areas are known to be 
involved in inhibitory control, and are regulated by the excitatory 
neurotransmitter glutamate (Naaijen et al., 2015, 2017, 2018). Within 
fronto-striatal circuity, the striatum is thought to be involved in driving 
the repetitive and compulsive behaviors, while frontal regions, such as 
the anterior cingulate cortex (ACC) is responsible for exerting inhibitory 
control (Naaijen et al., 2015; Bari and Robbins, 2013; Fineberg et al., 
2010; Aron et al., 2007; Aron and Poldrack, 2006; Dalley et al., 2011; 
Zandbelt et al., 2010). Imaging studies focusing on ASD and/or OCD 
have shown altered fronto-striatal structure and function as well as 
altered glutamate conentrations, suggesting a possible shared underly-
ing mechanism affecting repetitive and compulsive behaviors (Bari and 
Robbins, 2013; Fineberg et al., 2010; Chmielewski and Beste, 2015). 
Here, we investigated this by using a multi-center, longitudinal 
approach looking at associations of fronto-striatal glutamate and re-
petitive and compulsive behaviors on neural activity during inhibitory 
control in a childhood/adolescent cross-disorder population. 
In studies using the stop-signal task in ASD and OCD, there have been 
inconsistent results. Some studies found no behavioral differences in 
ASD and OCD compared with controls (Chantiluke et al., 2015; Albajara 
Sáenz et al., 2020; Gooskens et al., 2018), while others have found worse 
performance in participants with OCD (Chamberlain and Menzies, 2009; 
Chamberlain et al., 2007; Verbruggen and Logan, 2008; de Wit et al., 
2012; Penadés et al., 2007; Norman et al., 2019), demonstrating deficits 
in inhibitory control. However, these differences are more commonly 
found in adults with OCD than children and adolescents (Marzuki et al., 
2020). Altered activity in fronto-striatal areas during inhibitory control 
has been found in both disorders as well (Albajara Sáenz et al., 2020; 
Norman et al., 2019; Apergis-Schoute et al., 2018; Woolley et al., 2008; 
Carlisi et al., 2017), showing reduced activity during inhibition in ACC. 
Additionally, in ASD increased activation has been found in left striatum 
compared to controls, while this was decreased in OCD (Carlisi et al., 
2017). Contrarily, some studies found altered functional activity despite 
not finding behavioral differences in response inhibition compared to 
controls (Roth et al., 2007; Rubia et al., 2010). In a previous study using 
a partly overlapping sample of the current study, no behavioral or neural 
alterations were found during inhibitory control in participants with 
ASD and OCD (Gooskens et al., 2018). 
The excitatory neurotransmitter glutamate is highly relevant for 
proper fronto-striatal functioning as well as inhibitory control. Altered 
concentrations of glutamate, investigated using proton magnetic reso-
nance spectroscopy (1H-MRS), have been linked to repetitive behaviors 
and compulsivity (Naaijen et al., 2015; Silverman et al., 2008), which 
seem to differ in individuals with ASD and OCD compared to controls 
across development. A meta-analysis of 1H-MRS studies investigating 
fronto-striatal glutamate in the neurodevelopmental disorders ASD, 
OCD and attention-deficit/hyperactivity disorder (ADHD) reported that 
increased glutamate concentrations in striatum seems to be present 
across these disorders (Naaijen et al., 2015). In the ACC, on the other 
hand, glutamate concentrations were often higher in children and ado-
lescents with these disorders while in adults the opposite pattern was 
found, with lower concentrations compared to controls, suggesting a 
developmental shift (Naaijen et al., 2015). In a study investigating 
glutamate concentrations and neural functioning during inhibitory 
control, increased ACC glutamate was associated with decreased activity 
in striatum, but this was unrelated to any clinical diagnosis (Naaijen 
et al., 2018). 
Evidence from these previous studies strongly suggests that investi-
gating the interplay between glutamate and functional activity during 
inhibitory control is an important step for understanding the mecha-
nistic underpinnings of behaviors across neurodevelopmental disorders. 
In a study including the first time of measure of the participants in this 
study, increased ACC glutamate was found in both ASD and OCD, and a 
positive association between ACC glutamate and compulsive behaviors 
was found, while there were no group differences in striatal glutamate 
nor any association with behavior (Naaijen et al., 2017). In the current 
study we followed up this sample with a second timepoint of measure-
ments using a multimodal, multi-center study design. With this devel-
opmental data we aimed to investigate whether changes in fronto- 
striatal glutamatergic alterations and functioning during inhibitory 
control differed across (atypical) neurodevelopment and whether there 
were any changes over time. Based on previous findings, we expect 
increased glutamate concentrations in fronto-striatal brain regions in 
the ASD and OCD group, especially in the ACC. As repetitive and 
compulsive behaviors likely decrease over time, we expect inhibitory 
control to be associated with these behaviors differently over time. In 
addition, we expect a differential role for glutamate here, which may 
affect functioning differently in ASD and OCD as compared to the con-
trol group. These are exploratory analyses as the link between fronto- 
striatal functioning and neurochemistry has not been investigated in 
these groups before. 
2. Methods and materials 
2.1. Participants 
We included 74 participants (ASD = 24, OCD = 15, controls = 35) for 
the 1H-MRS analysis, between 8 and 16 years old at time-point 1 (T1), 
and between 9 and 17 years at timepoint 2 (T2). Our previous manu-
script describing the spectroscopy results of T1 included a total amount 
of n = 133 participants (Naaijen et al., 2017). Reasons for drop-out for 
this longitudinal study were loss of interest by the participants and 
quality restrictions regarding the spectra. For the combined 1H-MRS and 
fMRI analysis we included 53 participants. The participants were 
recruited at three different locations across Europe (Radboud University 
Medical Center and the Donders Institute for Brain, Cognition and 
Behavior, Nijmegen, The Netherlands (N = 38), Kings College London, 
London, United Kingdom (N = 17), Central Institute of Mental Health, 
Mannheim, Germany (N = 19)) in the multicenter study COMPULS, part 
of the TACTICS consortium (www.tactics-project.eu). Another site was 
excluded due to too few participants surviving quality control (N = 3). 
The inclusion criteria were IQ > 70, ability to speak and comprehend the 
native language of the location of recruitment and being of Caucasian 
descent (for further details, see (Naaijen et al., 2017). To confirm DSM- 
IV-TR (Association, 2000) diagnoses of ASD and OCD, we used the 
Autism Diagnostic Interview-Revised (ADI-R) (Lord et al., 1994) and 
Childreńs Yale Brown Obsessive Compulsive Scale (CYBOCS) (Scahill 
et al., 1997) for ASD and OCD respectively. Participants with ASD and 
OCD were not allowed to have a diagnosis of the other disorder of in-
terest. Control participants were confirmed to not score in the clinical 
range for any DSM IV axis I diagnoses using the Child Behavior Checklist 
(CBCL) and the Teacher Report Form (TRF) (Bordin et al., 2013), 
assessment of ADHD symptoms were measured using the Conners Parent 
Rating Scale (CPRS-R, (Conners et al., 1998). Repetitive and compulsive 
behaviors were measured using the Repetitive Behavior Scale – Revised 
(RBS-R) (Lam and Aman, 2007). Information on medication use was 
collected on the measurement days via parental report. Participants 
were asked to abstain from stimulant medication 48 h before scanning. 
None of the participants received non-pharmacological treatment dur-
ing the study. Ethical approval for the study was obtained for all centers 
separately and participants and their parents gave written informed 
consent for participation. 
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2.2. Stop-signal task 
To measure inhibitory control participants completed a modified 
visual version of the stop-signal task (SST) (Rubia et al., 2003) during an 
fMRI session. For details of the design of the task see Fig. S1 in the 
Supplementary material. To ensure consistency across sites, task in-
structions were given according to a standard operating procedure 
(SOP). 
2.3. Image acquisition 
Participants were familiarized with the MRI settings and practiced 
the SST using a dummy scanner at T1. At T2, the task was practiced 
again if needed. The data were acquired from the three study locations, 
all using 3 Tesla scanners (Siemens Trio and Siemens Prisma, Siemens, 
Erlangen, Germany; Philips Achieva, Philips Medical Systems, Best, The 
Netherlands; General Electric MR750, GE Medical Systems, Milwaukee, 
Wi, USA). Structural T1-weighted scans were acquired based on the 
ADNI GO protocols (Jack et al., 2008, 2010), which were used for 
registration of the functional scans and voxel placement for the 1H-MRS. 
Spectra were acquired using a point resolved spectroscopy sequence 
(PRESS) with a chemically selective water suppression (CHESS) (Haase 
et al., 1985) from the midline pregenual ACC and the left dorsal striatum 
covering caudate and putamen with an 8 cm3 voxel size (2 × 2 × 2). 
Voxel locations were adjusted to maximize the amount of grey matter 
(GM) and minimize the cerebrospinal fluid (CSF) content to keep the 
quality of the data as high as possible. The locations of all voxel place-
ments are shown in the Supplementary material (Fig. S2 and S3). Details 
on the structural, functional and 1H-MRS scan parameters can be found 
in Table S1 in the Supplementary material. 
2.4. Imaging analysis 
2.4.1. fMRI 
From the 74 participants included in analysis based on available MRS 
data, 53 had available fMRI data included in analysis (ACC: ASD = 15, 
OCD = 11, Controls = 27; Striatum: ASD = 13, OCD = 9, Controls, 24). 
Preprocessing of the fMRI data was performed using FSL (https://fsl. 
fmrib.ox.ac.uk/fsl/). The first five volumes from each scan were 
removed to account for equilibration effects. Head movement correction 
was performed by realigning to the middle volume (MCFLIRT; (Jen-
kinson et al., 2002)). A Gaussian kernel with full width at half maximum 
(FWHM) of 6 mm was used for grand mean scaling and spatial 
smoothing. ICA-AROMA (Pruim et al., 2015a, 2015b) was then used to 
remove signal components related to secondary-head motion artefacts, 
subsequently followed by nuisance regression to remove signal from CSF 
and white matter (WM), and high-pass filtering (100sec). These images 
were co-registered to each participants’ anatomical scan using 
boundary-based registration within FSL-FLIRT (Greve and Fischl, 2009). 
The anatomical scans were spatially normalized using a 12-parameter 
affine registration to MNI152 standard space, which was refined by 
non-linear registration FSL-FNIRT (Andersson et al., 2007). The images 
were then brought into standard space by applying the resulting warp 
fields to the concatenated functional image. Neural activation during 
inhibitory control was analyzed using SPM12 (Statistical Parametric 
Mapping release 12, https://www.fil.ion.ucl.ac.uk/spm/). For the 
whole-brain analysis during the stop-task, the first level models included 
two contrasts of interest; (American Psychiatric Association, 2013) 
failed stop – successful go, to isolate failed inhibitory control and 
(Robbins et al., 2012) successful stop – failed stop, to isolate successful 
inhibitory control. For the second level analyses regarding differences 
across groups and times of measure, we used a full-factorial design 
where t-contrasts were applied to the first level contrast maps. To 
investigate the association between our spectral data and the fMRI data 
we extracted the mean beta weights during both failed and successful 
inhibitory control from the ACC and dorsal striatum regions of interest 
as extracted from the 1H-MRS voxels. This was done using the MarsBar 
toolbox (Brett et al., 2002). 
2.4.2. 1H-Mrs 
Glutamate concentrations were estimated using Linear Combination 
Model (LCModel), using water as reference (Provencher, 2014, 2001). 
Example fitted spectra for ACC and striatum can be seen in Fig. 1. As 
different tissues contain different amounts of water, correction for tissue 
percentage and partial volume effects was calculated using the formula:  
where 43 300 is the water concentration in millimolar for GM, 35 880 
for WM and 55 556 for CSF, as described in the LCModel manual (Pro-
vencher, 2014). 
Criteria for quality control were the signal-to-noise ratio being ≥ 15, 
Cramér-Rao lower bounds ≤ 20%, and FWHM ≤ 0.1 parts per million. 
This resulted in 74 participants included in the analysis of ACC gluta-
mate (ASD = 24, OCD = 15, Controls = 35), and 55 participants 
included for striatal glutamate (ASD = 18, OCD = 11, Controls = 26). To 
check for possible influences of glutamine we performed quality controls 
of glutamine concentrations, which only survived quality control mea-
sures for one participant for the ACC voxel and ten participants for the 
striatum voxel. We therefore do not report Glx (glutamate + glutamine) 
measures and report only glutamate. The raw glutamate levels can be 
found in Table S3 in the Supplementary material. 
2.5. Statistical analyses 
Statistical analyses were performed using the R-software package 
(Booth et al., 2018), unless otherwise stated. 
We first investigated changes in fronto-striatal glutamate concen-
trations, neural activation and behavioral responses during inhibitory 
control over time separately. Changes in these scores over time were 
calculated by subtracting glutamate levels, or neural responses, in the 
spectral regions of interest and measures of compulsivity and inhibitory 
control at T1 from T2. These are reported as change-scores (Δ). Diag-
nosis, Δ RBS-R total and Δ RBS-R compulsivity scores were then used as 
predictors in separate models. Age, sex and scan-site were included as 
covariates of non-interest in all analyses; because age and sex did not 
affect the results nor influenced the model(s), they were removed from 
further analyses. To test general effects of time we used linear mixed 
effects models, where participant was added as a random factor to ac-
count for within subject variability across time (lme4 package (Bates 
et al., 2015)). Additionally, we investigated whether ADHD symptoms 
was associated with glutamate concentrations by including the CPRS-R 
scores in separate models. As there were no associations of ADHD 
symptoms, CPRS-R scores were not included in subsequent models in 
analyses. 
Secondly, we combined spectral and functional analyses into a multi- 
modal model investigating whether changes over time in one modality 
were associated with changes over time in the other modality using the 
Metabolitecorrected = MetaboliteRaw ×
(








V. Hollestein et al.                                                                                                                                                                                                                              
NeuroImage: Clinical 30 (2021) 102622
4
1H-MRS voxels as regions of interest. Specifically, we investigated 
whether changes in glutamate concentrations in either region 
(ΔGluACC/Str) were associated with changes in neural activation 
(ΔbetaACC/Str) in the same region and whether this was different across 
groups and continuous measures of repetitive behavior. This resulted in 
twenty-four models, which are shown in more detail in Table S2 in the 
Supplementary material. 
All reported p-values in all statistical tests are corrected for multiple 
Fig. 1. 1H-MRS voxel placement. A: Superposition on the MNI152 template of all individual voxel placements in ACC and striatum, for ASD (red), OCD (blue) and 
controls (yellow). The placements were consistent across diagnoses, as seen by the large overlap of voxels. For voxel placements across sites, see Supplementary 
material. B: Example spectra of a 3 T proton magnetic resonance spectroscopy (1H-MRS) Linear Combination (LC) Model spectral fit in ACC and striatum from one of 
the control participants. The top of the images represents the residuals. The black line represents frequency-domain data, the red line is the LCModel fit. The right 
images show the fits for glutamate only. For examples of LCModel spectral fits and glutamate fits for each site, see Fig. S5 in the Supplementary material. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 1 
Demographic characteristics (based on the largest subsample group in analysis).   
ASD  OCD  Controls  Test statistic p-value Post-hoc 
Sex, m/f 17/7  9/6  21/14  KWχ2 = 0.81  0.667   
Mean SD Mean SD Mean SD    
Age 1 11.38 1.64 11.95 2.49 10.70 1.38 KWχ2 = 5.61  0.061  
Age 2 12.92 1.62 13.38 2.51 12.20 1.46 KWχ2 = 5.27  0.072  
IQa 109.38 15.07 109.89 15.56 111.84 11.05 KWχ2 = 0.50  0.781   
RBS 1          
Total 24.86 24.46 15.67 19.09 0.80 2.14 KWχ2 = 49.75  <0.001 OCD & ASD > Controls 
Stereotype 2.79 3.27 2.00 2.80 0.06 0.24 KWχ2 = 31.44  <0.001 OCD & ASD > Controls 
Self-harm 1.38 2.06 1.40 2.77 0.06 0.34 KWχ2 = 20.18  <0.001 OCD & ASD > Controls 
Compulsivity 3.46 5.74 4.73 5.00 0.20 0.63 KWχ2 = 29.12  <0.001 OCD & ASD > Controls 
Ritualistic 5.17 6.03 3.73 4.30 0.08 0.28 KWχ2 = 40.04  <0.001 OCD & ASD > Controls 
Insist on sameness 9.71 8.61 2.87 5.89 0.26 0.92 KWχ2 = 42.22  <0.001 ASD > OCD & Controls 
Limited interests 2.46 2.78 0.93 1.16 0.14 0.36 KWχ2 = 20.42  <0.001 ASD & OCD > Controls  
RBS 2          
Total 20.61 19.48 11.86 9.71 0.46 1.06 KWχ2 = 44.26  <0.001 OCD & ASD > Controls 
Stereotype 2.26 2.25 1.71 1.69 0.03 0.17 KWχ2 = 31.99  <0.001 OCD & ASD > Controls 
Self-harm 1.96 3.62 0.71 1.69 0.00 0.00 KWχ2 = 16.68  <0.001 ASD > OCD & Controls 
Compulsivity 2.43 3.46 3.71 3.73 0.06 0.24 KWχ2 = 30.08  <0.001 OCD & ASD > Controls 
Ritualistic 3.83 4.31 2.29 2.91 0.12 0.33 KWχ2 = 20.17  <0.001 OCD & ASD > Controls 
Insist on sameness 7.63 6.34 2.07 2.62 0.18 0.53 KWχ2 = 37.76  <0.001 OCD > ASD > Controls 
Limited interests 2.30 2.75 1.36 1.45 0.06 0.24 KWχ2 = 24.63  <0.001 OCD & ASD > Controls  
MEDICATIONb          
Stimulant 2  0  0     
Antipsychotic 0  1  0     
Antidepressant 1  5  0     
ASD, Autism Spectrum Disorder; OCD, Obsessive Compulsive Disorder; SD, standard deviation; RBS, Repetitive Behavior Scale (Lam and Aman, 2007). KWχ2; Kruskal- 
Wallis Chi-Square. Post hoc tests were Bonferroni corrected. The number of participants per group is the largest subsample available across analyses. a IQ was collected 
during the first time of measure. b Medication use is indicated from first time of measure, changes in the second measure can be found in the supplementary material. 1 
and 2 in the left column indicate first (T1) and second (T2) point of measure. 
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comparisons by the false discovery rate (FDR, q < 0.05), unless other-
wise stated. Effect sizes are indicated as r. 
3. Results 
3.1. Demographics 
No differences were found between groups in age, IQ or sex. Table 1 
shows an overview of the demographics and clinical variables of the 
largest subsample used. For the repetitive and compulsive behaviors we 
used the RBS-R total scores and the compulsivity subscale scores at T1, 
T2 as well as the change over time (Δ). Although there was no general 
effect of time on these measures, there were significant differences be-
tween ASD, OCD, and controls at all time-points. See Fig. 2 for a sum-
mary of these results. 
3.2. Spectral quality 
Groups did not differ in mean voxel percentage GM, WM or CSF in 
both voxels (all p-values > 0.05). Percentage GM in striatum, however, 
was lower the second time of measure compared to the first one ((b =
−0.07, t(52) = −2.97, p = 0.004), independent of diagnosis. Voxel 
placement during T1 and T2 and across scan-sites can be seen in the 
Supplementary material in Figs. S2 and S3. No differences were found 
between diagnostic groups or time-points for any of the measures. The 
ASD group showed, compared with controls, an increase in glutamate 
Cramér-Rao lower bound (CRLB) over time (b = 0.009, t(71) = 2.49, p =
0.015), although with the highest CRLB of 14%, guaranteeing sufficient 
quality of these spectra at both timepoints (Kreis, 2016). 
3.3. Fronto-striatal glutamate 
There was a negative association between diagnosis and ΔGluACC (b 
=−1.55, t=(0.68) =−2.28, p = 0.026, r = 1.00), which indicated a larger 
decrease in ACC glutamate in ASD over time compared with controls, 
but not OCD (p > 0.05; Fig. 3A). In addition, the RBS-R total score was 
associated with ACC glutamate as well, where an increase over time in 
repetitive behaviors was related to a decrease over time in ACC gluta-
mate (b = −0.12, t(0.05) = −2.330, p = 0.026, r = 1.00; Fig. 3B). 
There was no effect of diagnostic status or any of the continuous 
measures on ΔGluStr (all p-values > 0.05). However, striatal glutamate 
decreased significantly over time, independent of diagnosis (b = −0.65, 
t(52) = −2.77, p = 0.023, r = 0.36). 
3.4. Stop-signal task 
All groups showed common patterns of brain activation during failed 
as well as successful inhibitory control, where there was activation in 
areas typically associated with inhibitory control, such as ACC and 
striatum (Fig. S4). No significant differences in neural activation be-
tween groups were found at any time-point in any of our contrasts (all p- 
values > 0.05). However, using continuous measures of compulsivity 
and our fronto-striatal regions of interest, we found an effect of Δ 
compulsivity on Δ striatal activity (b = 1.88, t(0.51) = 3.70, p = 0.002, r 
= 0.98) during failed inhibitory control, where an increase in compul-
sivity over time was associated with an increased striatal activation, 
reflecting higher activity at T2, compared to T1. Behavioral results 
regarding the SST are described further in the supplementary material. 
3.5. Association between fronto-striatal glutamate and functioning 
3.5.1. Failed inhibitory control 
During failed inhibitory control there was a negative interaction 
between diagnosis and ΔGluStr on ΔbetaStr. This interaction showed 
that in OCD, an increase in striatal glutamate over time was associated 
with a decrease over time in activity in the same region compared to 
controls (b =−7.46, t(2.19) =−3.412, p = 0.003, r = 0.92), and ASD (b =
7.73, t(2.30) = 3.36, p = 0.003, r = 0.91); see Fig. 4A. There was no 
significant difference between ASD and controls (all p-values > 0.05). 
No associations were found regarding the ACC or any interactions 
Fig. 2. Repetitive and compulsive behaviors. Group differences in RBS compulsivity (upper panel) and RBS total scores (lower panel) at T1, T2 and over time. The 
OCD (N = 15) group showed higher compulsivity than both ASD (N = 24) and controls (N = 35) at both time-points without any differences in changes. Total RBS 
scores were highest in the ASD group at both time-points while simultaneously they showed the largest decrease in these symptoms between T2 and T1. * p < 0.05, ** 
p < 0.01, *** p < 0.001. 
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between glutamatergic changes and continuous measures of compul-
sivity (all p-values > 0.05). 
3.5.2. Successful inhibitory control 
During successful inhibitory control, there was a positive interaction 
between diagnosis and ΔGluStr on ΔbetaStr. This time, again in OCD, an 
increase in striatal glutamate over time was associated with an increase 
in striatal activity control compared to controls (b = 0.96, t(0.41) = 2.33, 
p = 0.025, r = 0.96), and ASD (b = 1.04, t(0.43) = 2.40, p = 0.025, r =
0.96), see Fig. 4B. There was again no significant difference between 
ASD and controls (all p-values > 0.05) nor any other significant asso-
ciations for the ACC or continuous measures of compulsivity (all p- 
values > 0.05). 
4. Discussion 
This is the first study that used a multi-center, longitudinal, trans-
diagnostic approach to investigate the associations of repetitive behav-
iors and compulsivity with fronto-striatal glutamate concentrations and 
functioning during inhibitory control in a childhood/adolescent cross- 
disorder population. 
Our 1H-MRS only results showed that over time there was a reduc-
tion in ACC glutamate in the ASD group compared with controls, while 
an increase in repetitive behaviors over time was associated with 
decreased glutamate in the same region. Previous studies investigating 
children with ASD have shown higher glutamate concentrations in ACC 
(Bejjani et al., 2012; Hassan et al., 2013; Joshi et al., 2012), while 
studies looking at adults with ASD have found both lower and higher 
glutamate concentrations in ACC compared to controls (Naaijen et al., 
2015; Ford and Crewther, 2016). Our finding may therefore reflect 
changes in development in ASD being different from development in 
controls. We found no such differences in the OCD group, although they 
did not significantly differ from the ASD group either, and previous 
studies with OCD have shown inconsistent results (Naaijen et al., 2015). 
This may be due to a larger heterogeneity in the disorder, and future 
studies considering possible subtypes of OCD may successfully disen-
tangle such differing results. However, the previous study investigating 
an overlapping sample (however, larger) at T1 found increased ACC 
glutamate in both ASD and OCD (Naaijen et al., 2017). In the striatum 
we found that glutamate decreased over time independent of diagnosis. 
This is in line with the study that found no group differences in striatal 
glutamate during the first time of measure (Naaijen et al., 2017), which 
is reflected also at T2. Alterations in metabolite concentrations during 
development are also known to occur in controls (Horská et al., 2002), 
and our finding may reflect such development in striatum, independent 
of a clinical diagnosis. 
Regarding neural activation, we did not find any group differences, 
time effects nor effects of our continuous measures in our whole brain 
analyses for neither failed nor successful inhibitory control. This was in 
line with the findings of T1 by Gooskens et al. (2018). However, other 
studies with similar behavioral results still found altered brain activa-
tion during inhibitory control (Chantiluke et al., 2015; Norman et al., 
2019; Woolley et al., 2008; Carlisi et al., 2017; Rubia et al., 2010). 
Although we were not able to find any whole-brain differences, when we 
were looking at our region of interest, we found that an increase in 
compulsivity over time was associated with increased striatal activation 
over time, but only during failed inhibitory control. Increased compul-
sivity may thus be associated with more difficulties with inhibition, 
resulting in more striatal activity reflecting an increased cognitive de-
mand. Our longitudinal TACTICS study on inhibitory control in ASD and 
Fig. 3. ACC glutamate. A: Glutamate concentrations, shown in institutional units (i.u.), decreased over time in the ASD (N = 24) group (blue) compared with controls 
(N = 35) (grey). Plot was created using ggplot2 (Ginestet, 2011) and in-house adapted violin plots (Hintze and Nelson, 1998). * p < 0.05. B: Effects of changes of 
changes in RBS-R total score on changes in ACC glutamate (in i.u.). The linear regression line shows a negative association of Δ RBS-R total score with changes Δ ACC 
glutamate, independent of diagnosis. The shaded area represents the 95% confidence interval. Dots on the vertical dashed line represent participants that did not 
change in RBS-R total scores. Note: this figure shows raw data-points, not model estimates. (For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.) 
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OCD found improvements in SSRT over time, regardless of diagnosis 
(Gooskens et al., 2018). In our partly overlapping subsample in this 
study, as shown in the supplementary material, we do not replicate this 
finding but show that males performed better than females. The fact that 
we did not find a general improvement may, however, be due to a lack of 
power and/or a larger proportion of males in this subsample. 
Integrating all these analyses for the first time in a multi-modal 
fashion investigating the association between developmental changes 
in glutamate concentrations as well as fronto-striatal functioning 
resulted in differential findings across failed and successful inhibitory 
control. While during failed inhibitory control, OCD participants 
showed decreased striatal activity with an increase in striatal glutamate 
over time, the reverse was found for successful inhibitory control; 
increased concentrations were associated with increased activity, again 
in the OCD group. Both these findings were significant compared with 
controls as well as compared with ASD. These results suggest differential 
involvement of striatal glutamate in neural activation patterns in OCD 
compared with controls and ASD during different aspects of inhibitory 
control. In order to successfully inhibit responses, more glutamate 
resulted in more activity, suggesting a compensatory mechanism in 
order to fulfill the cognitive demands of the task, even though behav-
iorally there were no differences in performance. As these results show 
significant changes over time in our ~1 year time window between 
measurements, our results also suggest there may be critical differences 
in neural measurements in childhood/adolescent neurodevelopmental 
populations. This needs further investigation, but may explain incon-
sistent results in neuroimaging results with child/adolescent pop-
ulations in these disorders. 
Considering that the OCD group showed higher compulsivity scores 
compared to controls as well as compared to ASD without any changes 
over time (Fig. 2), associations of both changes of glutamate in OCD and 
compulsivity on striatal activity during failed inhibitory control may 
point towards the same mechanistic differences for achieving the same 
neural activation. A recent study using a network analysis has suggested 
that compulsivity as seen in OCD and repetitive behaviors as seen in ASD 
represent distinct features of these disorders (Ruzzano et al., 2015), 
rather than symptom overlap between the two; something that has also 
been suggested (Ivarsson and Melin, 2008; Bartz and Hollander, 2006). 
Our OCD and ASD results do not overlap, but were found within the 
different regions of the fronto-striatal circuit (OCD findings in the 
striatum, ASD findings in the ACC). This indeed suggests that compul-
sivity in OCD and repetitive behaviors in ASD have distinct mechanistic 
underpinnings that are regionally specific and differently regulated by 
glutamate, despite the seemingly similar behavioral phenotypes. 
Considering the very limited research on these measures during 
adolescence, even more so in OCD than in ASD, these results are an 
important step towards increasing understanding of underlying mech-
anisms of development in compulsivity-related disorders. Further 
studies should confirm this initial finding, but this may contribute to 
targeted glutamate altering interventions in OCD. 
Strengths of the current study are combining categorical and 
dimensional analyses, with a longitudinal approach to investigate the 
relationship between repetitive and compulsive behaviors, fronto- 
striatal glutamate as well as functioning. There were also some limita-
tions. Firstly, the OCD group was smaller than the ASD group, which 
may have led to less power and the possibility of false negatives. How-
ever, we still found significant associations with changes in glutamate 
concentrations affecting changes in functional activity in OCD. 
Furthermore, the percentage GM in striatum decreased over time, sug-
gesting worse voxel placement. However, these changes were not 
different across diagnostic groups and therefore probably did not affect 
our main findings. As ability to speak their native language and IQ > 70 
were inclusion criteria in this study, this may have resulted in excluding 
what is often considered “low functioning” ASD participants. Therefore, 
our ASD specific results may not be generalizable to the entire popula-
tion of individuals with ASD. There are also difficulties performing 
multicenter studies, where data quality may differ across sites. However, 
we did manage to control for these effects in our models and our results 
were likely not affected by left-over site effects. Future studies should 
use a true longitudinal model with a longer time-period in between as 
Fig. 4. Failed and Successful inhibitory control. A: During failed inhibitory control, an increase in striatal glutamate (i.u.) was associated with a decrease in striatal 
BOLD signal in the OCD (N = 9) group (salmon) compared to controls (N = 24) (grey) and ASD (N = 13) (blue). B: During successful inhibitory control, an increase in 
striatal glutamate (i.u.) was associated with an increase in striatal BOLD in the OCD group compared to controls and ASD. Brain activity is shown on the axial slice for 
both failed and successful inhibitory control outlining the striatal voxel as an overlay. Activity is presented at p < 0.01 (uncorrected) for visualization purposes. The 
shaded areas represent the 95% confidence intervals. Note: This figure shows raw data-points, not model estimates. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web version of this article.) 
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well as preferably a larger sample size to increase the understanding of 
these integrated mechanisms underlying ASD and OCD. To further 
investigate similarities and differences between these disorders 
regarding compulsivity and repetitive behaviors we also suggest using a 
larger battery of measures of compulsivity and repetitive behaviors, to 
disentangle what variations of these features differ between these 
diagnostic groups, and what their underlying mechanisms are. 
5. Conclusion 
In conclusion we found, over time, significant associations in OCD of 
increased glutamate concentrations in striatum with decreased func-
tional activity in striatum during failed inhibitory control, and an 
opposite effect of increased striatal glutamate concentrations with 
increased striatal activity during successful inhibitory control. Increased 
compulsivity was also associated with increased striatal activity during 
failed inhibitory control. While glutamatergic alterations were differ-
ently involved during neural activation in OCD, there were no general 
changes in glutamate in the OCD group over time compared with con-
trols. In ASD on the other hand, we found ACC glutamate to decrease 
more over time compared with controls. These results should be repli-
cated in an independent sample, but this study has given new insights 
into the alterations of glutamate in ASD and OCD during development in 
adolescence, and its role in functional activity. 
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